131885-33-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-N-isopropyl-2-nitroaniline is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Fluoro-N-isopropyl-2-nitroaniline is utilized as a building block for the production of various agrochemicals. Its versatile reactivity allows for the creation of compounds that can be used in crop protection and other agricultural applications.
Used in Dye Industry:
5-Fluoro-N-isopropyl-2-nitroaniline is employed as a key intermediate in the synthesis of dyes. Its distinct properties enable the development of dyes with specific color characteristics and performance attributes, catering to various industrial needs.
Used in Fine Chemicals Industry:
As a versatile intermediate, 5-Fluoro-N-isopropyl-2-nitroaniline is used in the production of other fine chemicals. Its potential for forming complex molecules makes it a valuable component in the synthesis of specialty chemicals for various applications.
Safety Precautions:
Given its potentially hazardous nature, it is crucial to follow proper safety protocols when handling and working with 5-Fluoro-N-isopropyl-2-nitroaniline. This includes wearing appropriate personal protective equipment, ensuring proper ventilation, and adhering to established safety guidelines to minimize risks associated with its use.

Upstream product

• 700-36-7 2-bromo-4-fluoronitrobenzene 
• 75-31-0 isopropylamine 
• 446-35-5 2,4-Difluoronitrobenzene 

Downstream Products

• 709029-40-3 4-imidazol-1-yl-N²-isopropyl-benzene-1,2-diamine 
• 709029-42-5 (2-nitro-5-pyrrol-1-yl-phenyl)isopropylamine 
• 131885-72-8 N-(5-imidazol-1-yl-2-nitrophenyl)isopropylamine 
• 1026934-69-9 5-fluoro-N¹-isopropylbenzene-1,2-diamine 

Relevant academic research and scientific papers

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.

BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY

This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointe

Characterization of a new class of selective nonsteroidal progesterone receptor agonists

The identification of a new series of selective nonsteroidal progesterone receptor (PR) agonists is reported. Using a high-throughput screening assay based on the measurement of transactivation of a mouse mammary tumor virus promoter-driven luciferase reporter (MMTV-Luc) in human breast cancer T47D cells, a benzimidazole-2-thione analog was identified. Compound 1 showed an apparent EC50 of 53nM and efficacy of 93% with respect to progesterone. It binds to PR with high affinity (Ki=89nM), but had no or very low affinity for other steroid hormone receptors. Structure-activity relationship studies of a series of benzimidazole-2-thione analogs revealed critical positions for high PR binding affinity and transactivation potency as well as receptor selectivity, as exemplified by 25. Compound 25 binds to human PR with high affinity (Ki=28nM) and had at least >1000-fold selectivity for PR versus other steroid receptors. Molecular modeling studies suggested that these agonists overlap favorably with progesterone in the ligand-binding domain of PR. In T47D cells, compound 25 acted as a full agonist in the MMTV-Luc reporter assay, as well as in the induction of endogenous alkaline phosphatase activity with apparent EC50 values of 4 and 9nM, respectively. In the immature rat model, compound 25 provided a significant suppression of estrogen-induced endometrium hypertrophy as measured by luminal epithelial height. In contrast, compound 25 was inactive in the luteinizing hormone release assay in young ovariectomized rats. These benzimidazole-2-thione analogs constitute a new series of nonsteroidal PR agonists with an excellent steroid receptor selectivity profile. The differential activities observed in the in vivo progestogenic assays in rat models suggest that these analogs can act as selective PR modulators.

3-Phenyl-substituted imidazo[1,5-a]quinoxalin-4-ones and imidazo[1,5- a]quinoxaline ureas that have high affinity at the GABA(A)/benzodiazepine receptor complex

A series of imidazo[1,5-a]quinoxalin-4-ones and imidazo[1,5- a]quinoxaline ureas containing substituted phenyl groups at the 3-position was developed. Compounds within the imidazo-[1,5-a]quinoxaline urea series had high affinity for the GABA(A)/benzodiaze